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Abstract: Ovarian cancer ranks amongst the deadliest cancers in the gynaecological category of cancers.
This research work aims to evaluate in vitro anti-ovarian cancer activities and identify phytochemical
constituents of a rarely explored plant species—Rutidea parviflora DC. The aqueous and organic extracts
of the plant were evaluated for cytotoxicity using sulforhodamine B assay in four ovarian cancer cell
lines and an immortalized human ovarian epithelial (HOE) cell line. The bioactive compounds were
isolated and characterized by gas/liquid chromatography mass spectrometry and nuclear magnetic
resonance spectroscopy. Caspase 3/7 activity assay, western blotting and flow cytometry were carried
out to assess apoptotic effects of active compounds. The extracts/fractions of R. parviflora showed
promising anti-ovarian cancer activities in ovarian cancer cell lines. A principal cytotoxic alkaloid was
identified as palmatine whose IC50 was determined as 5.5–7.9 µM. Palmatine was relatively selective
towards cancer cells as it was less cytotoxic toward HOE cells, also demonstrating interestingly
absence of cross-resistance in cisplatin-resistant A2780 cells. Palmatine further induced apoptosis by
increasing caspase 3/7 activity, poly-ADP-ribose polymerase cleavage, and annexin V and propidium
iodide staining in OVCAR-4 cancer cells. Our studies warranted further investigation of palmatine
and R. parviflora extracts in preclinical models of ovarian cancer.
Keywords: Ovarian cancer; Rutidea parviflora; Palmatine; Apoptosis
Key Contribution: Palmatine, a quaternary protoberberine alkaloid, has been isolated and identified
from an unexplored Nigerian plant—Rutidea parviflora DC. for the first time. It showed potent
cytotoxicity against ovarian cancer cells via apoptosis induction.
1. Introduction
Ovarian cancer is a significant and global threat to life in women. American cancer society
estimated that 22,240 of new ovarian cancer diagnosed and 14,070 ovarian cancer deaths are projected
to occur in the United States in 2018 [1]. It is ranked 5th most common cause of death among
women in the UK. There were 7270 new cases of ovarian cancer in 2015 and 4227 cases of ovarian
cancer-related deaths in 2016 in the UK. The ten year survival rate (2010–2011) remains just 35% [2].
Epithelial ovarian cancer can be subdivided into at least four major histological subtypes: serous,
endometrioid, clear cell and mucinous carcinoma [3]. High-grade serous ovarian cancer (HGSOC), the
most aggressive subtype, is responsible for 70–80% of all ovarian cancer deaths; the overall survival
rate has not changed significantly for several decades [4,5]. Ovarian cancer is typically diagnosed
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at a late stage and no effective screening strategy exists. The current standard treatment for ovarian
cancer entails surgery aimed at removing most of the cancerous cells, followed by the administration
of chemotherapeutics, often resulting in multiyear survival [4]. However, use of chemotherapy
introduces drug resistance and consequently subsequent relapse can lead to the death of the cancer
patients [6,7]. For example, platinum-based drugs are initially effective against HGSOC, but recurrent
tumors resistant to these agents have developed later on [8]. Recently, three novel poly-ADP-ribose
polymerase (PARP) inhibitors such as olaparib, rucaparib, and niraparib have been approved by the
US Food and Drug Administration and European Medicines Agency for the treatment of ovarian
cancer caused by the alteration of DNA damage repair pathways [9]. Despite of these significant
achievements, investigation into the discovery of new drugs that may offer wider therapeutic benefits
by overcoming resistance mechanisms and drug toxicity in ovarian cancer therapy is still an unmet
need in the light of the ovarian cancer menace.
The use of plants in the treatment of cancer is not new because there is documented evidence
of the use of medicinal plants for the treatment of cancer [10–12]. A number of plant-derived or
semi-synthetic anti-ovarian cancer drugs including paclitaxel, etoposide and topotecan have been
approved and widely used in clinic [13,14]. Previously, we identified cytotoxic cyclotides from a
Chinese medicinal plant [15], a cytotoxic indolizine alkaloid, securinine [16,17], and three cytotoxic
bisbenzylisoquinoline alkaloids, cycleanine [18–20], isochondodendrine and 2’-norcocsuline [21,22] in
Nigerian medicinal plants. Semi-synthetic cycleanine [23] and thymoquinone [24] analogues were
further prepared and evaluated for their in vitro anti-ovarian cancer activities. In continuation of our
search for novel anti-ovarian cancer compounds, we evaluated an unexplored Nigerian medicinal
plant—Rutidea parviflora DC. (family Rubiaceae) [17].
R. parviflora has been used for anti-inflammatory and anti-cancer activities among the indigenous
communities in Delta state of Nigeria. The fruits are taken to induce vomiting and for the treatment
of convulsions, epilepsy, spasm and paralysis [25]. However, there are no pharmacological and
phytochemical studies reported. In this study, we report the extraction, isolation and identification
of cytotoxic palmatine from R. parviflora, and its induction of apoptosis leading to ovarian cancer
cell death.
2. Results
2.1. Bioassay-Guided Isolation and Identification of Palmatine
Both the organic and aqueous extracts of R. parviflora inhibited growth of the cultures with IC50
values of <10 µg/ml in OVCAR-4, OVCAR-8, A2780, and cisplatin resistant A2780 (A2780cis) ovarian
cancer cell lines. Solvent partition of the organic extract yielded n-hexane, ethyl acetate, n-butanol and
aqueous fractions. The n-butanol fraction showed the most potent cytotoxic effects followed by the
ethyl acetate fraction (Table 1).
Bioassay-guided fractionation and isolation of the bioactive compounds of R. parviflora was carried
on the most potent n-butanol and ethyl acetate fractions. Nine sub-fractions were obtained from the
column fractionation of the n-butanol fraction. HPLC purification of the most potent sub-fraction
3 was carried out to obtain a yellow powder, which was determined as palmatine (1) (Figure 1) by
liquid chromatography coupled with mass spectrometry (LC-MS) (Figure S1), NMR spectroscopy and
comparing with a standard palmatine.
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Table 1. Cytotoxicity (IC50) and selectivity index (SI) of the extracts, fractions, and isolated compounds
of R. parviflora in ovarian cancer cell lines and an immortalized human ovarian epithelial (HOE) cell
line after 72 h treatment. IC50 is the half maximal inhibitory concentration of extracts, fractions, or
compounds. SI is a ratio of the measured IC50 value against HOE to the measured IC50 value against
each cancer cell line. The results are expressed as mean ±SEM (n = 3). n.d., not determined.
Extract, Fraction and
Compounds
OVCAR-4 OVCAR-8 A2780 A2780cis HOE
(µg/ml)
Organic extract 6.6 ± 1.6 8.7 ± 0.5 3.2 ± 0.3 n.d. n.d.
Aqueous extract n.d. 5.9 ± 0.03 2.2 ± 0.5 3.7 ± 0.03 n.d.
n-Hexane fraction 23.3 ± 1.0 18.3 ± 0.3 7.3 ± 0.8 n.d. n.d.
Ethyl acetate fraction 5.4 ± 0.3 5.8 ± 0.4 2.5 ± 0.2 n.d. n.d.
n-Butanol fraction 2.6 ± 0.1 2.6 ± 0.3 1.7 ± 0.2 n.d. n.d.
Aqueous fraction 22.9 ± 1.3 22.1 ± 1.1 12.8 ± 1.3 n.d. n.d.
(µM)
Palmatine (1) 7.4 ± 0.3 7.9 ± 0.5 6.6 ± 0.5 5.5 ± 0.9 25.1 ± 5.0
SI for 1 3.4 3.2 3.8 4.6 -
Urs-12-en-24-oic acid,
3-oxo-, methyl ester (2) 85.4 ± 2.4 48.9 ± 2.0 31.6 ± 3.3 n.d. >200
SI for 2 >2 >4 >6.5 - -
Carboplatin 11.1 ± 0.4 10.8 ± 1.3 16.0 ± 1.0 >100 15.2 ± 3.0
SI for carboplatin 1.4 1.4 0.95 <0.15 -
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. c e ical structure of palmatine (1) and urs-12-ene-24-oic acid, 3- xo, methyl ester (2)
isolated from R. parviflora.
Palmatine (1) showed potent cytotoxicity with IC50 (5.5–7.9 µM) in four ovarian cancer cell lines,
but less cytotoxic to human ovarian epithelial (HOE) cell. The selectivity indexes (SI) of palmatine for
cancer cells compared to HOE cells ranged from 3–5, while the SI of the clinically used carboplatin
and paclitaxcel [24] only showed around 1–1.5 (Table 1). Further bioassay-guided fractionation of
ethyl acetate fraction yielded urs-12-ene-24-oic acid, 3-oxo, methyl ester (2), which exhibited moderate
inhibition of the growth of ovarian cancer cell cultures and also showed apparently mild effect on HOE
cells (Table 1). Compound 2 has been previously identified by gas chromatography coupled with mass
spectrometry (GC-MS) analysis from the ethanolic extract of Canscora perfoliata used in the treatment of
poisonous bites [26].
2.2. Apoptosis Studies
2.2.1. Caspase 3/7 Activity and Western Blotting Analysis
In order to investigate the possible route of cell death caused by the compounds, the effect of
palmatine on the activity of caspase 3/7 to evaluate apoptosis was determined in a selected OVCAR-4
cell line. It was derived from HGSOC tumor sample and regarded as one of the most suitable models
of ovarian cancer [3]. Figure 2A demonstrated that palmatine as well as positive control-carboplatin
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significantly increased caspase 3/7 activity in comparison to the vehicle-treated cells for an experimental
period of 48 h.
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Figure 2. (A) The effect of carboplatin and palmatine (each 10 µM) on the caspase 3/7 activity at
48 h in OVCAR-4 cells. The caspase activity was easur d and normalized with corresponding
sulforhodamine B (S B)-stained cells to estimate the surviving cell umber. **** denotes that the result
is significantly different (p < 0.001). The results were expressed as mean ±SEM, n = 3. (B) Detection
of poly-ADP-ribose polymerase (PARP) cleavage by immunoblotting. OVCAR-4 cells were treated
with palmatine (10 or 20 µM) and carboplatin (40 µM) for 48 h. The vehicle-treated cells served as
the control.
To confirm that the compounds induced apoptosis, caspases mediated cleavage of PARP was
assessed by immuno-staining. As expected, significant PARP cleavage in OVCAR-4 cells was observed
after treatment of palmatine and carboplatin (Figure 2B).
2.2.2. Flow Cytomet ic Analys s
Further investigation of the apoptosis inducted by palmatine (1) was carried out by means of
annexin V/propidium iodide (PI) labelling, followed by flow cytometry analysis. Palmatine (1) induced
concentration–dependent increase in the population of OVCAR-4 cells in the early and late stage
of apoptosis compared to the control (Figure 3). The morphological changes of cells treated with
palmatine were monitored microscopically at 48–72 h. The characteristic features of apoptosis such as
blebbing and shrinkage of cells were also clearly observable by microscopy (Figure S2).
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Figure 3. Flow cytometry analysis of the apoptotic effect of palmatine on OVCAR-4 cells after annexin
V/PI staining. OVCAR-4 cells were treated with palmatine (10 or 20 µM) and carboplatin (20 or 40 µM)
for 48 h. The vehicle-treated cells were used as the control. A representation of the quantification of
the combined early and late phase apoptotic cells is shown. **, ***, and **** denote that the results
are significantly different from the control with p < 0.01, 0.005, and 0.001, respectively. n.s. indicates
p > 0.05. The results were expressed as mean ±SEM, n = 3.
3. Discussion
The phytochemical and pharmacological characterization of R. parviflora was carried out in this
study. Significa t cytotoxic activities of both organic and aqueous extracts were demonstrated in
ovarian cancer cells. Here we focused on the organic extract, however, different water-soluble and
bioactive compounds could be discovered in the aqueous extract. From the organic extract, two
cytotoxic compounds: palmatine (1), a quaternary protoberberine alkaloid, and urs-12-ene-24-oic-acid,
3-oxo, methyl ester (2), a triterpenoid, were isolated and identified for the first time. Palmatine showed
significant inhibitory activity in the cell growth assay. Palmatine did show some preferential selective
cytotoxicity for cancer cells, with slightly less potent inhibition of the growth of HOE cells (Table 1).
The killing of cancer cells by the compound was likely to occur through induction of apoptosis,
evidenced by significant increase in caspase 3/7 activity (Figure 2A), PARP cleavage (Figure 2B),
annexin V/propidium iodide labelling of cells (Figure 3). PARP cleavage is a well-established method
of demonstrating apoptosis as PARP is a substrate for caspase 3 and 7 and is cleaved in the course
of apoptosis into two fragments [27,28]. PARP is a DNA repair nuclear enzyme which detects DNA
fragmentation [29]. The cleavage of PARP-1 thus is a confirmation of apoptosis. This enzyme has
been a validated drug target of developing successful PARP inhibitors for the treatment of ovarian
cancer [10]. It is of interest to note that palmatine showed greater potency and selectivity compared to
carboplatin. Importantly, it demonstrated an absence of cross-resistance in cisplatin-resistant A2780
cells (IC50 = 6.6 µM for A2780, and 5.5 µM for A2780cis cells). Because drug resistance still remains
one of the main causes of failure for ovarian cancer treatment using platinum compounds [8].
Palmatine was previously found to be present in Rhizoma coptidis, an important medicinal plant
commonly used in the traditional Chinese medicine [30] and the butanol fraction of Phellodendron
amurense bark extract [31]. Our result is in agreement with the reported cytotoxicity of palmatine in
prostate cancer cells [31] and breast cancer MCF-7 cell line [32]. In prostate cancer cells, the ribosomal
protein S6, a downstream target of p70S6K and the Akt/mTOR signaling cascade was identified as
a potential target of palmatine. Selective cytotoxicity of palmatine against prostate cancer cells was
also reported [31]. Palmatine was shown to inhibit growth of pancreatic stellate cells (PSCs) and
cancer cells alone or in combination with gemcitabine [33]. Such inhibition of growth and migration of
pancreatic cancer cells was due to its suppression of glutamine-mediated changes in glioma-associated
oncogene 1 (GL1) signalling, and induction of apoptosis [33]. Palmatine was found to be mainly located
in endoplasmic reticulum and mitochondria of MCF-7 cells [33]. Further photodynamic treatment
demonstrated photocytotoxicity of the naturally occurring photosensitizer palmatine in breast cancer
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MCF-7 [33] and colon adenocarcinoma HT-29 cells [34], causing significant cell apoptosis and increased
intracellular reactive oxygen species levels. Palmatine has also been found to bind and stabilize
parallel G-quadruplex DNA, indicating that it may be an inhibitor of telomere elongation and oncogene
expression in humans [35]. Recently, palmatine from another traditional Chinese medicine Mahonia
bealei was demonstrated to improve the survival of mice with colorectal cancer via the inhibition of
inflammatory cytokines [36]. In the future work, it is necessary to test if palmatine behaves similar
mechanism of action in ovarian cancer cells as those found in other cancers, and also to investigate its
efficacy and safety in animal models of ovarian cancer.
4. Materials and Methods
4.1. Plant Material and Reagents
The stem bark of R. parviflora was collected in Delta state, Nigeria in February 2014. The plant
was authenticated by A.O. Oziokowith of University of Benin, Nigeria. A voucher specimen
(INTERCEDD/1588) was deposited in the herbarium at the International Centre for Ethnomedicine
and Drug Development (INTERCEDD), Enugu state, Nigeria. Trichloroacetic acid (TCA) was
purchased from Fisher Scientific (Loughborough, United Kingdom) Carboplatin, glacial acetic acid,
N,O-bis(trimethylsily) trifluoroacetamide (BSTFA) with 1% chlorotrimethylsilane (TMCS), palmatine
chloride, pyridine, sulforhodamine B (SRB) sodium salt, Trypsin-EDTA solution, and Trizma base
were purchased from Sigma Aldrich (Gillingham, United Kingdom). Fetal bovine serum (FBS),
penicillin-streptomycin, and RPMI 1640 medium were purchased from Lonza (Visp, Switzerland).
4.2. Extraction of Plant Materials
The plant materials were extracted according to the reported method [37]. The stem bark powder
(1 kg) was macerated in a mixture of dichloromethane and methanol (1:1) for three times. The obtained
residue was further macerated in methanol to yield the methanol extract. Both extracts were combined
and evaporated to yield the total organic extract (7.2 g). Water was then added to the plant residue to
obtain the aqueous extract (1.5 g) after freeze drying. The organic extract of R. parviflora was further
partitioned in water using different organic solvents to obtain the n-hexane fraction (2.0 g), the ethyl
acetate fraction (1.3 g), the n-butanol fraction (0.9 g) and the aqueous fraction (0.5 g).
4.3. Analysis of the Bioactive Fraction of R. parviflora by Gas Chromatography–Mass Spectrometry (GC–MS)
The bioactive fraction (1.0 mg) and isolated compound (2) of R. parviflora was incubated with
10 µl of pyridine and 50 µl of BSTFA (with 1% TMCS) in the oven at 37 ◦C for 2 h. The resulting
trimethylsilyl (TMSi) derivatives were submitted to GC–MS analysis [16,38,39].
4.4. Liquid Chromatography Mass Spectrometry (LC-MS) Analysis
The isolated compounds were analysed by LC-MS, to determine their molecular mass, and their
retention times compared with purchased standard compounds. The Agilent technologies 1260 Infinity
coupled to 6530 Accurate mass Q-TOF LC-MS system was used (Agilent Technologies, Santa Clara, CA,
USA). The gas temperature was 320 ◦C, with a dry gas flow rate of 11 L/min. Electrospray ionization
(ESI) was operated at a voltage of 4000 V, an m/z range of 100–2000. The samples were injected at
a volume of 5 µl and the run time was 15 min. The data was analysed by the Agilent mass-hunter
qualitative analysis software.
4.5. NMR Spectroscopy
1H NMR spectra of the isolated compounds in CDCl3 or CD3OD were obtained with a Bruker 1D
(DPX-300) NMR spectrometer for 300 MHz (Bruker, Billerica, MA, USA), and Bruker 1D (DPX-500) for
500 MHz. 13C NMR spectra were obtained at 125 MHz with a Bruker NMR spectrometer. ACD/Labs
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10 Freeware (Advanced Chemistry Development Inc., Toronto, ON, Canada) was used in the Analysis
of the NMR Spectra.
4.6. Purification and Isolation of Bioactive Compounds
The n-butanol fraction was submitted to silica gel column chromatography by eluting with ethyl
acetate/methanol. Sub-fractions were subjected to high performance liquid chromatography (HPLC)
on a semi-preparative column with a mobile phase composition of 0.1% trifluoroacetic acid (TFA) as
solvent A and 80% acetonitrile with 0.1% TFA as solvent B. The gradient began with 100% of A for
5 min and increased to 80% B over 25 min. Then the gradient was increased to 100% B and maintained
for 6 min. Palmatine (10 mg, 1) was obtained as a yellow powder. LC positive ESI-MS, m/z: 352.1548
(Figure S1). 1H NMR (500 MHz, CD3OD), δ 9.76 (1H, s, H-8), 8.80 (1H, s, H-13), 8.12 (1H, d, J = 9.0 Hz,
H-11), 8.01 (1H, d, J = 9.1 Hz, H-12), 7.67 (1H, s, H-1), 7.05 (1H, s, H-4), 4.92 (2H, t, J = 6.5 Hz, H-6), 4.21
(3H, s, OCH3), 4.11 (3H, s, OCH3), 3.99 (3H, s, OCH3), 3.94 (3H, s, OCH3), 3.28 (2H, t, J = 6.4 Hz, H-5).
13C NMR (125 MHz), δ 152.5, 150.5, 149.5, 145.0, 144.4, 138.5, 133.9, 128.7, 126.7, 123.0, 121.9, 119.9,
119.1, 110.8, 108.6, 61.1 (OCH3), 56.3 (OCH3), 55.9 (OCH3), 55.6 (CH2), 55.3 (OCH3), 26.4 (CH2). These
data are consistent with those reported [40,41].
The ethyl acetate fraction (RP-EA) of R. parviflora was also fractionated on silica gel column with a
solvent gradient range of 100% n-hexane to 100% ethyl acetate to yield ten sub-fractions. Sub-fraction
F2 was treated with hot methanol and recrystallized at a temperature of 4 ◦C to yield a white crystal
(yield: 12.8%), urs-12-ene-24-oic acid, 3-oxo, methyl ester (2), referring as EA2 (Figure 1), by GC-MS
and 1H NMR. EI-MS, m/z (%): 468 [M]+ (2), 453 (1), 218.2 (100), 203.2 (15), 189.2 (21), 178.1 (6), 161.1
(10), 135.1 (18), 21.1 (17), 95.1(22), 81.1 (18), 69.1 (20), 43.1 (48). 1H NMR (300 MHz, CDCl3) δ: 5.27 (brs),
3.49 (s, 3H, O-CH3), 1.90-2.32 (m), 0.80-1.70 (m). Its 1H NMR is consistent with those reported [42].
4.7. Cell Culture
The human ovarian cancer cell lines, OVCAR-4, OVCAR-8, A2780, cisplatin-resistant A2780
(A2780cis) were bought from American Type Culture Collection (Manassas, VA, USA), and human
ovarian epithelial (HOE) cells immortalized using SV40 large T antigen (Catalogue number: T1074)
were purchased from Applied Biological Materials Inc. (Richmond, BC, Canada). All cells were
cultured in Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with 10% fetal bovine
serum (FBS), penicillin-streptomycin (50 U/ml) and glutamine (2 mM).
4.8. Cell Growth Assay
TheSRB assay was used to evaluate the effects of the plant extracts and pure compounds on the
growth of ovarian cancer and HOE cell lines after treatment of 72 h [16,20,43]. 100 mg/ml concentrations
of the plant extracts were prepared using dimethyl sulfoxide (DMSO) (organic extracts) and media
(aqueous extracts) as stock solutions. 20 mM of purified compounds (1 and 2) and carboplatin were
prepared in DMSO and used in the assay. The 0.1% DMSO in growth media was added to the cells;
referred to as vehicle-treated cells (control). Nine concentrations of the drugs were prepared by using a
two-fold serial dilution. Each well of the 96-well plates were seeded with 80 µl of the ovarian cancer
and HOE cells at a density of 2000 cells/well, except for OVCAR-4 which was plated at a density
of 5000 cells/well. After 24 h, 20 µl of plant extracts (1 mg/ml) after further 100-fold dilution of the
stock solution in the medium or pure compounds were added and the cell cultures were kept in the
incubator at 37 ◦C under 5% CO2 for 72 h in a humidified atmosphere. The medium was decanted and
the cells fixed with 10% TCA on ice for 30 min and dried. The dried plates were stained with 0.4%
SRB for 30 min, washed with 1% acetic acid and dried. 100 µL of Tris-base (10 mM) were added to the
plates and shaken for 10 min to solubilise the protein-bound SRB dye. The absorbance at 570 nm was
measured using a multi-mode microplate reader BioTEK Synergy 2 (Winooski, VT, USA). The recorded
data was analysed by non-linear regression using the GraphPad PRISM software (GraphPad Software
v6.0, San Diego, CA, USA) to fit a 4 parameter sigmoidal dose-response curve to determine IC50 values
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and the Hill coefficient. Based on the mean IC50s obtained, the selectivity index (SI) was calculated for
each bioactive compound and carboplatin using the following formula:
SI =
IC50 (HOE cell line)
IC50 (cancer cell line)
(1)
The SI value obtained is an indication of the preferential selectivity in the cytotoxicity of the
compound for cancer cells. A large value suggests that the compound would be more cytotoxic to
cancer cells than HOE cells.
4.9. Caspase 3/7 Activity
Caspase 3/7 activity was measured in cells pre-treated with vehicle (0.1% DMSO in growth
medium), carboplatin, palmatine (1) and urs-12-ene-24-oic acid, 3-oxo, methyl ester (2) by use of the
caspase 3/7 Glo-reagent obtained from Promega (Southampton, UK). For the determination of caspase
3/7 activity, OVCAR-4 cells were seeded in 96-well plates at a density of 5000 cells/well, and exposed to
the compounds at different concentrations for 48 h. Then 25 µl of caspase 3/7 Glo-reagent was carefully
added to the cells in the dark. The foiled plates were placed on a rocker for 30 min before measurement
of luminescence.
4.10. Western Blotting
The measurement of PARP cleavage was carried out as described previously [20]. Briefly, six-wells
plates seeded with OVCAR-4 cells at a density of 300,000/well and treated with 0.1% DMSO vehicle,
10 µM or 20 µM of palmatine or 40 µM of carboplatin for 48 h. The cells were collected, trypsinized,
washed with cold phosphate buffered saline (PBS) and lysed with radioimmunoprecipitation assay
(RIPA) buffer consisting of 20 mM Hepes, 150 mM NaCl, 2 mM EDTA, 0.05 mM pepstatin, 0.12 mM
leupeptin, 1 mM phenylmethylsulfonyl fluoride, 0.5% sodium deoxycholate and 1% NP40.
The protein concentrations were evaluated by the bicinchoninic acid (BCA) Assay. About
10 µg protein of each cell lysate sample was carefully added to NuPAGE sample buffer made up
with 5% β-mercaptoethanol, before electrophoresis using sodium dodecyl sulphate polyacrylamide
gel electrophoresis (SDS-PAGE), for 15 min at a temperature of 70 ◦C to denature the proteins.
The denatured proteins were added to a 4–20% Tris-Glycine polyacrylamide gradient gel to separate
the proteins from the cell lysates using 100 mM Hepes, 100 mM Tris and SDS (1%) as running buffer.
The separated proteins were transferred to Amersham Hybond P (GE Healthcare Life Sciences,
Buckinghamshire, UK) 0.45 µm polyvinylidene difluoride membrane and incubated in transfer
buffer with a composition of 200 mM glycine, 25 mM Tris, 10% methanol and 0.075% SDS for 1.5 h.
The membrane was again incubated in Tris buffered saline with tween (TBST, 150 mM NaCl, 0.1%
Tween 20, 50 mM Tris hydrochloride, and 5% skimmed milk powder, pH 7.4) for 1.5 h on a rocker
at room temperature to achieve blocking of the membranes. The membrane was subsequently
incubated overnight at 4 ◦C in the buffer with primary antibody against poly-ADP-ribose polymerase
(Catalogue number: 9542, Cell Signaling Technology Inc., London, UK) (1:1000) and antibody
against glyceraldehde-3-phosphate dehydrogenase (GAPDH) (Catalogue number: MAB374, Millipore,
Watford, UK) (1:5000). The membrane was washed several times with TBST, before incubation in the
buffer with IgG secondary antibody conjugated with horseradish peroxidase (HRP) (Catalogue number:
7074, Cell Signaling Technology Inc.) (1:2000) for 1 h at room temperature on a rocker. Following several
washes in TBST, the membrane was analyzed on a FluorChem M Imager (ProteinSimple, San Jose, CA,
USA), for the visualization of the protein bands using the UptiLight HRP chemiluminescent substrate
according to the manufacturer’s instructions (Uptima, San Jose, CA, USA).
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4.11. Flow Cytometry
Flow cytometry analysis of annexin V/PI labelled treated cells were carried out as described as
before [20,21]. Briefly, OVCAR-4 cells were seeded into 12-well plates and exposed to the treatment
compounds at the indicated concentrations, followed by annexin V labelling of the cells using an
annexin V-FITC kit procured from Miltenyi biotech (Bergisch Gladbach, Germany).
4.12. Statistical Analysis
The cytotoxicity, caspase activity and flow cytometry results were presented as mean values ±
standard error of means (SEM). Statistical analysis was performed using one-way analysis of variance
(ANOVA) and GraphPad Prism software v6.0 for the determination of statistical significance of
difference between means. p < 0.05 were considered statistically significant.
5. Conclusions
In conclusion, this is the first report of the cytotoxic activities of R. parviflora, a medicinal plant,
from folk medicine in Nigeria. Palmatine was isolated and identified from this unexplored plant, which
provides a new source of palmatine. This study has also shown that palmatine possesses cytotoxicity,
with apoptosis as the route of cell killing. Therefore, palmatine is a potential lead compound for the
development of treatment of ovarian cancer, and merits further investigation.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6651/11/4/237/s1,
Figure S1: LC-MS chromatogram and MS of palmatine isolated from Rutidea parviflora. Figure S2: The effects of
palmatine (20 µM) on cell morphology of OVCAR-4 cells monitored by light microscope for 48–72h.
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